Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis

Abroad (travel likely)Recruiting

Conditions

Multiple Sclerosis (MS) - Relapsing-remitting

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University of Maryland, Baltimore, Baltimore, Maryland, United States
Contact: Study coordinator (Kerry Naunton, RN) · knaunton@som.umaryland.edu · 410-328-1885
Contact: Study coordinator (Daniel Harrison, MD) · dharrison@som.umaryland.edu · 410-328-5605
Contact: Principal Investigator (Daniel Harrison, MD)
Osamah Saeedi, MD (Sub-investigator)

Study leads

Daniel Harrison, MD
Principal Investigator
University of Maryland, Baltimore

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

Multiple Sclerosis · Multiple Sclerosis (MS) - Relapsing-remitting

Abroad (travel likely)RecruitingPHASE4

Chicago, United States

Effects of Ublituximab on Motor Functions in Multiple Sclerosis

Multiple Sclerosis (MS) - Relapsing-remitting

Abroad (travel likely)RecruitingEARLY_PHASE1

Atlanta, United States · Atlanta, United States

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

Multiple Sclerosis (MS) · Multiple Sclerosis, Relapsing-Remitting · Multiple Sclerosis, Primary Progressive

Abroad (travel likely)RecruitingPHASE1, PHASE2

San Francisco, United States

Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis

Multiple Sclerosis

Abroad (travel likely)RecruitingPHASE4

Kaohsiung City, Taiwan · Taichung, Taiwan